STOCK TITAN

Oramed Pharmaceuticals, Inc - ORMP STOCK NEWS

Welcome to our dedicated news page for Oramed Pharmaceuticals (Ticker: ORMP), a resource for investors and traders seeking the latest updates and insights on Oramed Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oramed Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oramed Pharmaceuticals's position in the market.

Rhea-AI Summary
Oramed Pharmaceuticals appoints Benjamin Shapiro to its Board of Directors. Mr. Shapiro is a successful entrepreneur and media professional. He owns over 4% of Oramed's stock. His addition is expected to bring value to the company and its shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.53%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.77%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-76.46%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.66%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.25%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.52%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.74%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.19%
Tags
conferences clinical trial
Oramed Pharmaceuticals, Inc

Nasdaq:ORMP

ORMP Rankings

ORMP Stock Data

118.32M
36.70M
11.23%
13.91%
1.19%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About ORMP

oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg